A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-08

Study Completion Date

2022-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study was to evaluate whether the safe-use conditions for administration of brexanolone (ZULRESSO®) can be implemented in a home setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)

NCT04273191

Postpartum Depression

WITHDRAWN PHASE4

A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

NCT06057012

Severe Postpartum Depression

COMPLETED PHASE2

A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy

NCT07047820

Depression, Postpartum

RECRUITING

Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression

NCT05543746

Postpartum Depression

COMPLETED

A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression

NCT06285916

Depression, Postpartum Postpartum Depression Post-partum Depression +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postpartum Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ZULRESSO®

Participants received a 60-hour single continuous intravenous (IV) infusion of ZULRESSO®, at 30 micrograms per kilogram per hour (mcg/kg/hour) (0 to 4 hours), at 60 mcg/kg/hour (4 to 24 hours), at 90 mcg/kg/hour (24 to 52 hours), followed by a dose taper to 60 mcg/kg/hour (52 to 56 hours), and 30 mcg/kg/hour (56 to 60 hours) during the study.

Group Type EXPERIMENTAL

ZULRESSO®

Intervention Type DRUG

Intravenous infusion of ZULRESSO®.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ZULRESSO®

Intravenous infusion of ZULRESSO®.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Allopregnanolone Brexanolone SAGE-547

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ambulatory female ≥18 years of age.
2. Participant has a current diagnosis of postpartum depression (PPD), as confirmed by the investigator.
3. Participant agrees not to be the primary caregiver of any dependents during the infusion and must be accompanied by another adult (other than the home healthcare provider) during interactions with their child(ren).
4. Participant has no history of sleep apnea or any clinically significant respiratory conditions.
5. Participant agrees to refrain from the use of central nervous system depressants, such as opioids, benzodiazepines, sleep aids and from drinking alcohol during the infusion.
6. Participant is suitable for administration of ZULRESSO® in a home setting, as per the judgement of the investigator.
7. Participant's home is suitable and has necessary provisions for administration of ZULRESSO® and meets the following criteria:

* safe environment for the home infusion provider staff.
* access to a working telephone.
* electricity and grounded electrical outlets.
* running water.
* access to back-up emergency services (911 service or ambulance availability).
* sanitary environment.
8. Participant agrees to stay at home until the end-of-study visit has been completed, except for a medical emergency.
9. Participant must have a negative pregnancy test at screening and on Day 1 prior to the start of the ZULRESSO® infusion.

Exclusion Criteria

1. Participant has end stage renal failure.
2. Participant has known allergy to progesterone or allopregnanolone or any excipients in the brexanolone injection.
3. Participant is currently at risk of suicide, as judged by the investigator, or has attempted suicide associated with the current episode of PPD.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No